Peer-reviewed results from the phase 3 X-TOLE2 trial, published in JAMA Neurology, detail azetukalner's seizure reduction and dose-dependent adverse events in adults with focal epilepsy.
In the prespecified mild subgroup of HOPE, 40-Hz gamma sensory stimulation was associated with 56% slowing on the ADCS-ADL and 47% slowing on the CDR-SB vs sham at 12 months.
Angela Lek, PhD, chief research officer at the Muscular Dystrophy Association, discussed how the 2027 MDA Clinical and Scientific Conference agenda reflects key themes in neuromuscular medicine.
A new global phase 2 trial, TARBELA-AD, will test RG6434, Roche's investigational oral NLRP3 inflammasome inhibitor, in adults with early symptomatic Alzheimer disease.
Nick Cunniffe, MD, PhD, assistant professor and consultant neurologist at the University of Cambridge, discusses lessons from a decade of proof-of-concept remyelination trials in MS.
Laurie Gutmann, MD, chair of the Department of Neurology at Indiana University School of Medicine, discusses one-year pooled ACHIEVE data for z-basivarsen (DYNE-101), an investigational antisense oligonucleotide, in myotonic dystrophy type 1 (DM1).